INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics to Participate in Upcoming May Investor Events
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics Provides Corporate Update
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next?
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade
Compass Therapeutics to Participate in Upcoming December Investor Events
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics Announces Proposed Public Offering
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference